Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q2 EPS of ($1.10), $0.09 worse than the analyst estimate of ($1.01).

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.